乳腺癌的免疫治疗策略：临床更新。
Immunotherapeutic strategies in breast cancer: A clinical update.
机构信息
Department of Surgery, Breast Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, New York, USA.
出版信息
J Surg Oncol. 2021 Mar;123(3):710-717. doi: 10.1002/jso.26287. Epub 2020 Nov 6.
Abstract
Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.
摘要
免疫疗法已被纳入多种恶性肿瘤的标准治疗方案。肿瘤浸润淋巴细胞的研究强调了宿主抗肿瘤免疫反应在乳腺癌自然史中的重要性。最近的临床试验已经使用免疫治疗方法来增强这种反应，并改善乳腺癌患者的预后。在这里，我们回顾了几项当前的临床试验数据，这些数据表明检查点阻断可能介导临床显著的反应。
相似文献
1
Immunotherapeutic strategies in breast cancer: A clinical update.乳腺癌的免疫治疗策略：临床更新。
J Surg Oncol. 2021 Mar;123(3):710-717. doi: 10.1002/jso.26287. Epub 2020 Nov 6.
2
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.肿瘤浸润淋巴细胞亚群在乳腺癌中的预后和治疗作用。
Cancer Metastasis Rev. 2021 Jun;40(2):519-536. doi: 10.1007/s10555-021-09968-0. Epub 2021 May 7.
3
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.乳腺癌的联合放射治疗与免疫检查点阻断治疗
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26.
4
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.PD-1/PD-L1 阻断免疫疗法在乳腺癌中的现状。
Jpn J Clin Oncol. 2021 Mar 3;51(3):321-332. doi: 10.1093/jjco/hyaa230.
5
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.肿瘤浸润淋巴细胞及免疫疗法在乳腺癌中的新作用
Pathology. 2017 Feb;49(2):141-155. doi: 10.1016/j.pathol.2016.10.010. Epub 2016 Dec 31.
6
T-cell-based breast cancer immunotherapy.基于 T 细胞的乳腺癌免疫疗法。
Semin Cancer Biol. 2021 Jul;72:90-101. doi: 10.1016/j.semcancer.2020.05.019. Epub 2020 May 31.
7
Advancing Immunotherapy in Metastatic Breast Cancer.转移性乳腺癌的免疫治疗进展
Curr Treat Options Oncol. 2017 Jun;18(6):35. doi: 10.1007/s11864-017-0478-9.
8
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
9
Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.重建乳腺癌免疫监测：分子病理生理学和当前免疫治疗策略。
Int J Mol Sci. 2021 Nov 6;22(21):12015. doi: 10.3390/ijms222112015.
10
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer.将免疫疗法纳入早期乳腺癌（新）辅助治疗。
Curr Opin Oncol. 2020 Nov;32(6):575-584. doi: 10.1097/CCO.0000000000000675.
引用本文的文献
1
Differential Gene Analysis of Trastuzumab in Breast Cancer Based on Network Pharmacology and Medical Images.基于网络药理学和医学图像的曲妥珠单抗在乳腺癌中的差异基因分析
Front Physiol. 2022 Jul 8;13:942049. doi: 10.3389/fphys.2022.942049. eCollection 2022.
2
A Tumor Suppressor Gene-Based Prognostic Classifier Predicts Prognosis, Tumor Immune Infiltration, and Small Molecule Compounds in Breast Cancer.基于肿瘤抑制基因的预后分类器可预测乳腺癌的预后、肿瘤免疫浸润及小分子化合物
Front Genet. 2022 Feb 3;12:783026. doi: 10.3389/fgene.2021.783026. eCollection 2021.
3
Exercise Training Improves Tumor Control by Increasing CD8 T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.运动训练通过 CXCR3 信号增加 CD8 T 细胞浸润来改善肿瘤控制，并使乳腺癌对免疫检查点阻断敏感。
Cancer Immunol Res. 2021 Jul;9(7):765-778. doi: 10.1158/2326-6066.CIR-20-0499. Epub 2021 Apr 10.
本文引用的文献
1
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比：一项随机、双盲、III 期试验（IMpassion031）。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
2
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.帕博利珠单抗联合化疗作为高危早期三阴性乳腺癌的新辅助治疗：来自 1b 期开放标签、多队列 KEYNOTE-173 研究的结果。
Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14.
3
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
4
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.帕博利珠单抗联合新辅助化疗对早期乳腺癌患者病理完全缓解的影响：正在进行的 2 期适应性随机 I-SPY2 试验分析。
JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650.
5
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.阿替利珠单抗联合白蛋白紫杉醇作为不可切除的局部晚期或转移性三阴性乳腺癌（IMpassion130）的一线治疗：一项随机、双盲、安慰剂对照、III 期临床试验的更新疗效结果。
Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.
6
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.全面分析贫困风险原发性和复发性三阴性乳腺癌配对样本揭示免疫表型转变。
Clin Cancer Res. 2020 Feb 1;26(3):657-668. doi: 10.1158/1078-0432.CCR-19-1773. Epub 2019 Oct 14.
7
Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.PD-1/PD-L1 在原发性乳腺肿瘤和转移性腋窝淋巴结中的表达及其与临床病理参数的相关性。
Sci Rep. 2019 Oct 7;9(1):14356. doi: 10.1038/s41598-019-50898-3.
8
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.早期三阴性乳腺癌（TNBC）患者未接受辅助化疗时肿瘤浸润淋巴细胞的预后价值。
Ann Oncol. 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395.
9
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.一项随机 II 期研究，旨在探讨在早期三阴性乳腺癌中，在蒽环类药物紫杉烷为基础的新辅助治疗中加入度伐利尤单抗的效果：GeparNuevo 研究的临床结果和生物标志物分析。
Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.
10
Current Landscape of Immunotherapy in Breast Cancer: A Review.乳腺癌免疫治疗的现状：综述
JAMA Oncol. 2019 Aug 1;5(8):1205-1214. doi: 10.1001/jamaoncol.2018.7147.
Zotero 插件